论文部分内容阅读
目的探讨拓扑异构酶Ⅱα(TOP2α)在前列腺组织中的表达,明确其在前列腺癌中的意义。方法回顾性分析58例前列腺病理切片,其中30例确诊为前列腺癌(前列腺癌组),28例为良性前列腺增生(良性前列腺增生组),58例标本均进行拓扑异构酶Ⅱα表达的免疫组织化学染色,分析比较两组患者的拓扑异构酶Ⅱα阳性表达情况,分析前列腺癌组Gleason评分与拓扑异构酶Ⅱα表达的关系。结果拓扑异构酶Ⅱα表达情况:前列腺癌组中26例(86.7%)阳性表达,而良性前列腺增生组中5例(17.9%)阳性表达,两组比较差异具有统计学意义(χ~2=27.560,P=0.000<0.05)。前列腺癌组Gleason评分≥7分时,拓扑异构酶Ⅱα阳性表达为16例;而Gleason评分<7分时,拓扑异构酶Ⅱα阳性表达为10例,比较差异具有统计学意义(χ~2=5.275,P<0.05)。结论应用拓扑异构酶Ⅱα检测有助于辅助前列腺癌的诊断,而Gleason评分增高,拓扑异构酶Ⅱα的表达增高。
Objective To investigate the expression of topoisomerase Ⅱα (TOP2α) in prostate tissue and to clarify its significance in prostate cancer. Methods A retrospective analysis of 58 cases of prostate pathology, including 30 cases of prostate cancer (prostate cancer group), 28 cases of benign prostatic hyperplasia (benign prostatic hyperplasia group), 58 cases of topoisomerase Î ± Î ± expression of the immune tissue The expression of topoisomerase Ⅱα in the two groups was analyzed by chemical staining. The relationship between the Gleason score and the expression of topoisomerase Ⅱα in prostate cancer was analyzed. RESULTS: The expression of topoisomerase Ⅱα was positively expressed in 26 cases (86.7%) in prostate cancer group and 5 cases (17.9%) in benign prostatic hyperplasia group, the difference was statistically significant (χ ~ 2 = 27.560, P = 0.000 <0.05). The positive expression of topoisomerase Ⅱα was 16 cases when the Gleason score ≥7 in the prostate cancer group, while 10 cases was positive for topoisomerase Ⅱα in the Gleason score <7, the difference was statistically significant (χ ~ 2 = 5.275, P <0.05). Conclusions The detection of topoisomerase Ⅱα is helpful for the diagnosis of prostate cancer, while the Gleason score is increased and the expression of topoisomerase Ⅱα is increased.